Background: Enzyme replacement therapy significantly reduces morbidity and mortality in patients with Pompe disease. Development of hypersensitivity reactions to enzyme replacement therapy is common and can adversely affect disease outcomes when treatment is halted or delayed.
Introduction
Pompe disease (PD) is a rare inherited disorder caused by mutations in acid-alpha-glucosidase (GAA) gene that codes for the enzyme alpha-glucosidase. Alpha-glucosidase is responsible for breakdown of glycogen into glucose for energy use. Loss of function of this enzyme results in accumulation of glycogen predominantly in skeletal muscle fibres. There is a wide clinical spectrum of this disease ranging from lethal infantile onset form to progressive late onset form characterized by varying degree of muscle weakness, respiratory insufficiency and eventual death usually from respiratory failure. 1 Incidence of Pompe disease varies amongst different ethnicities with a reported incidence amongst Chinese population of 1 in 50,000. 2
Report of Case
This is a 9-year-old Chinese girl born to non-consanguineous parents. She presented at 7 months with hypotonia, delayed motor milestones and cardiac failure secondary to hypertrophic cardiomyopathy. Investigations revealed deficient GAA activity in both skin fibroblast cells (1.06 nmol/hr/mg protein; control reference 260 nmol/hr/mg protein) and blood spot (3.9 pmol/punch/hour; control reference 10.0-49.0 pmol/ punch/hour). DNA sequencing for GAA gene was also done that confirmed presence of a homozygous GAA mutation involving single nucleotide change (c.1935C>A) in exon 14 which is a common mutation seen in the Chinese population. 6 This assay used polymerase chain reaction amplification followed by Sanger DNA sequencing to detect mutations in the GAA gene that cause Pompe disease. Cross-reactive immunologic material (CRIM) status was positive in our patient and was determined via Western Blot analyses on cell lysates derived from skin fibroblast cells. GAA protein bands were identified using a pool of polyclonal antibodies made against placental GAA protein that recognised both processed and unprocessed forms of GAA protein. Her other comorbidities include restrictive lung disease requiring nocturnal bi-level positive pressure ventilation and gastro-oesophageal reflux disease for which a gastrostomy creation and fundoplication was done. She is at present wheelchair-bound and fully assisted in her activities of daily living.
She was treated with Myozyme infusion at 20 mg/kg commencing at 9 months of age. In September 2016, 6 years after initiation of ERT, she developed hypersensitivity reactions. She was noticed to have an urticarial rash over the neck and forehead within two hours onset from infusion administration but otherwise no hemodynamic or respiratory compromise. step, temporarily halting the infusion and pre-medicating with steroids or anti-histamines. However, if these measures fail, desensitisation is strongly indicated.
Step Concentration (mcg/ml) For the subsequent Myozyme infusions, she was pre-medicated with cetirizine, prednisolone and the infusion was slowed to a third of the initial rate. In spite of the instituted measures, she developed significant and persistent urticaria. She was unable to complete her full dose of Myozyme for four cycles. Desensitisation was proposed after a multi-disciplinary discussion involving genetics-metabolic team, allergy team and pharmacists. Her parents gave informed consent. Skin prick test was negative, with histamine control 8.5 mm, negative control 0 mm, Myozyme (neat, 5 mg/ml) 2 mm. She was negative for recombinant alpha-glucosidase (rhGAA) IgG antibodies as determined by enzyme-linked immunosorbent assay (ELISA, Genzyme Laboratory). We did not perform rh-GAA IgE antibodies and intra-dermal skin test. She was commenced on the first desensitisation protocol adapted from El-Gharbawy et al's report published in 2011. 7 Her total dose was dropped to 10 mg/kg weekly and administered via the protocol shown in Table 1 , with stepwise 10-fold dose increments. However, she continued to develop significant urticarial rashes at point of escalation to 500 mcg/kg/hr of Myozyme infusion rate. The patient was clinically stable, however there was generalized and distressing urticarial rash which progressed despite administration of repeated doses oral non-sedative antihistamine (cetirizine). Thus, only 1.5 mg/kg (15%) of the intended dose was completed.
From the first desensitisation attempt, pertinent learning points were firstly the crucial role of pharmacist involvement to prepare Myozyme microdilution at timely intervals as the diluted solutions can only last for 24 hours. Pre-diluting the whole batch beforehand resulted in wastage of an expensive drug when protocol duration was prolonged secondary to urticarial reactions. Secondly, our patient fared better with conversion to a gentle 3-fold concentration increment, adopted from a case description by Karagol et al. 8 For the second infusion using the new protocol and pre-medication of oral prednisolone, she experienced reactions similarly at Table 1 .
Enzyme replacement therapy desensitization in a child with infantile onset Pompe disease and non IgE mediated mechanisms of IgG antibodies with complement activation, 7 cytokine release, 11 and direct mast cell stimulation. 5 As IARs of various mechanisms have similar presentations, clinicians are unable to use clinical history to predict and guide management. In case reports of IgE mediated IAR, skin prick test was negative in all patients and IgE sensitisation was proven by anti-rhGAA IgE and intradermal testing of varying concentration from 1:1000 8 to 1:100. 10, 12 For our patient, an IgE mediated mechanism was highly likely given her negative anti-rhGAA IgG and a skin prick test that measured 2 mm above negative diluent. After discussion with her parents, factoring in potential discomfort with intradermal testing and health resources, we proceeded with desensitisation therapy without pursuing the cause of IAR mechanism.
As recommended in the 2010 European Academy of Allergy and Clinical Immunology (EAACI) consensus statement on rapid desensitisation for drug hypersensitivity, 13 when the drug involved is essential for optimal therapy, desensitisation may be performed. Desensitisation is the induction of a temporary state of tolerance by introducing the culprit drug in increasing subtherapeutic doses. Desensitisation is performed only in IgE independent or IgE dependent reaction in which mast cell degranulation occurs. 14 Whilst desensitisation to Myozyme has been reported in literature, the numbers are small and mostly published as case reports 11 or case series 12 500 mcg/kg/hr requiring a decrease in infusion rate to 250 mcg/kg/hr and gradual increase up to 2000 mcg/kg/hr (2 mg/ kg/hr) with rashes noted at each two-fold concentration increment. Despite reactions, she was able to complete the full Myozyme dose on the second cycle. After modification and tailoring for the patient's response, we present the final steps of our desensitisation protocol in Table 2 . After 7 infusion cycles, we were able to stop pre-medications and after 9 infusion cycles, we were able to successfully convert the patient back to full dose of 20 mg/kg Myozyme and compress increment steps for shorter infusion duration. Three years on from initial desensitisation, she is tolerating her 2-weekly Myozyme infusions well.
Step Concentration (mcg/ml) 
Discussion
IAR to Myozyme are frequent in patients with Pompe disease. 3 A Phase III trial of Myozyme in infantile onset Pompe disease highlighted that 11 of the 18 patients experienced 164 IARs of mild to moderate severity including rash, fever, urticaria and desaturation. 9 IARs were typically managed by slowing or interrupting infusions. However, adjustment of infusion rate and administration of pre-medications were ineffective in our patient.
The immunologic mechanisms behind IARs are not well understood. Postulations include IgE mediated mechanisms 10 with less than 10 patients per published protocol. The first protocol we used from Gharbawy was a simple 10-step, 10fold escalation protocol with clearly stipulated rescue medications and safety guidelines. Unfortunately for our patient, the concentration escalation was too rapid and she continued to have distressing reactions prompting a change to the Karagol protocol. The main difference between our protocol and the original Karagol protocol was the more gradual stepwise dose escalation from step 13 onwards. Whilst it is common to get breakthrough reactions at the first course of desensitisation, our team opted to modify desensitisation protocol based on individual patient response.
One of the key predictors of ERT tolerance is the cross-reactive immunologic material (CRIM) status of the patient. Patients with detectable endogenous GAA are CRIM positive and tend to tolerate ERT well. In contrast, patients without detectable endogenous GAA are CRIM negative, develop high and sustained IgG antibody titres to exogenous recombinant GAA (rhGAA), and associated with poor tolerance and efficacy of ERT resulting in poor clinical outcomes. In patients who are CRIM negative, immunomodulation is an option in IgG antibody naïve patients as prophylaxis and patients with high antibody titres as treatment. Modalities of immunomodulation include rituximab, methotrexate and intravenous immunoglobulins. 15, 16 As our patient was CRIM positive and anti-rh-GAA IgG negative, immunomodulation was not an option.
In conclusion, it is possible to safely desensitise PD patients with ERT hypersensitivity for continuation of outcome modifying treatment. Desensitisation involves the multidisciplinary cooperation of nurses, pharmacists and doctors in the allergy, genetics and inpatient-monitoring team. Desensitisation protocols need to be tailored according to the patient's needs and responses to find a protocol that is safe, effective and simple.
